From: Epigenetic remodelling in human hepatocellular carcinoma
DRUGS | Phase | Reference |
---|---|---|
DNMTi | ||
Guadecitabine (SGI-110) after sorafenib | Phase II | NCT01752933 |
Guadecitabine (SGI-110) + durvalumab | Phase Ib | NCT03257761 |
HDACi | ||
Belinostat (PDX-101) | Phase I/II | NCT00321594 |
Tefinostat | Phase I/II | NCT02759601 |
Vorinostat + FOLFIRI | Phase I | NCT00537121 |
Panobinostat + sorafenib | Phase I | NCT00823290 |
Panobinostat + sorafenib | Phase I | NCT00873002 |
Resminostat + sorafenib | Phase II | NCT00943449 |
Resminostat + sorafenib | Phase I/II | NCT02400788 |
Vorinostat + sorafenib | Phase I | NCT01075113 |